BioSig Technologies says top-rated leading hospital system has purchased its PURE EP systems for multiple campuses in its national network

BioSig Technologies, Inc. (NASDAQ:BSGM) has announced that a top-rated leading hospital system has purchased the company’s PURE EP systems for multiple campuses in its national network.

“We are pleased to expand our commercial installations across this most important healthcare system in multiple states.” commented Kenneth L. Londoner, chairman and CEO of BioSig Technologies in a statement.  “We expect to see further commercial sales in coming weeks and months”

More than 680 patient cases have been conducted with the PURE EP System to date across eight clinical sites. The PURE EP System is being used in all types of arrhythmia cases, including atrial fibrillation, ventricular tachycardia, and atrial flutter.  The company said it continues to accumulate significant amounts of data to be utilized in the development of its AI platform.

READ: BioSig Technologies awarded US patent claims for noise-filtering methods of signal processing technology

The company previously announced that it completed its first commercial sale of PURE EP Systems to St. David’s HealthCare of Austin, Texas, an HCA Healthcare-owned hospital.

“We are excited to see leading electrophysiologists and institutions commercially adopt the PURE EP system which we believe demonstrates acceptance of the unique benefits of our system platform, software, and data,” added Londoner.

BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals.

PURE EP System, the company’s first product, is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

Contact the author at [email protected]

Story by ProactiveInvestors